ClinicalTrials.gg

Program

Budesonide

Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.

Furthest: phase 4, since Sep 27, 2005163 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca692 open or runningphase 4since Sep 27, 2005Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Dr. Falk Pharma171 open or runningphase 3since Mar 7, 2006Mar 7, 2006Dec 2026phase 3 · NCT06596252
Bausch Health Companies91 open or runningphase 4since Mar 17, 2020May 14, 2008Dec 2026phase 4 · NCT04314375
Takeda60 open or runningphase 3since Nov 4, 2015Sep 29, 2008none ahead
AbbVie50 open or runningphase 3since Dec 5, 2007Oct 30, 2007none ahead
Calliditas Therapeutics AB51 open or runningphase 4since Nov 20, 2024Oct 5, 2008Mar 2027phase 4 · NCT06712407
Intech Biopharm50 open or runningphase 2since Jun 11, 2014Jun 11, 2014none ahead
Chenpon Pharmaceutical30 open or runningphase 3since Aug 24, 2026Aug 24, 2026none ahead
Eurofarma Laboratorios30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Novartis30 open or runningphase 4since Feb 15, 2013Feb 15, 2013none ahead
Orion Corporation, Orion Pharma30 open or runningphase 2since Aug 24, 2009Aug 24, 2009none ahead
Padagis30 open or runningphase 3since Sep 28, 2011Sep 28, 2011none ahead
aquilon-pharmaceuticals-s-a20 open or runningphase 2since May 31, 2021May 31, 2021none ahead
bond-avillion-2-development-lp20 open or runningphase 3since Nov 30, 2018Nov 30, 2018none ahead
Ferring Pharmaceuticals20 open or runningphase 3since Jan 22, 2018Jan 22, 2018none ahead
Ligand Pharmaceuticals20 open or runningphase 2since Jul 13, 2009Jul 13, 2009none ahead
pari-pharma-gmbh20 open or runningphase 2since Sep 4, 2013Sep 4, 2013none ahead
Teva Pharmaceutical Industries20 open or runningphase 3since Feb 12, 2014Feb 12, 2014none ahead
triastek-lnc22 open or runningphase 1since Oct 13, 2026Oct 13, 2026Dec 2026phase 1 · NCT07897240
vectura-limited20 open or runningphase 1since Jan 12, 2018Jan 12, 2018none ahead
Zambon SpA20 open or runningphase 1since Sep 2, 2014Sep 2, 2014none ahead
Abbott10 open or runningphase 1since Jul 26, 2022Jul 26, 2022none ahead
Ache Laboratorios Farmaceuticos10 open or runningphase 3since Jul 25, 2016Jul 25, 2016none ahead
activaero-gmbh10 open or runningphase 2since Sep 10, 2010Sep 10, 2010none ahead
bazell-pharma-ag10 open or runningphase 2since Jan 3, 2022Jan 3, 2022none ahead
Chiesi Farmaceutici10 open or runningphase 3since May 18, 2007May 18, 2007none ahead
cipla-ltd10 open or runningphase 3since Mar 31, 2022Mar 31, 2022none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Apr 18, 2021Apr 18, 2021none ahead
Hamad Medical11 open or runningphase 3since May 25, 2015May 25, 2015none ahead
Johnson & Johnson10 open or runningphase 4since Oct 17, 2019Oct 17, 2019none ahead
kindeva-drug-delivery10 open or runningphase 3since Jan 6, 2017Jan 6, 2017none ahead
Lunan Pharmaceutical Group10 open or runningno phasesince Mar 29, 2025Mar 29, 2025none ahead
marinomed-biotech-ag10 open or runningphase 3since Nov 21, 2018Nov 21, 2018none ahead
rafa-laboratories10 open or runningphase 3since Aug 9, 2005Aug 9, 2005none ahead
unither-pharmaceuticals-france10 open or runningphase 1since Sep 6, 2024Sep 6, 2024none ahead

Also a collaborator on its studies: parexel, fortrea, takeda-development-center-americas-inc, iqvia-pty-ltd, premier-inc, Hikma Pharmaceuticals, cosmo-technologies-ltd, map-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-allerga, q-pharm-pty-limited and Kyowa Kirin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 1, 2015.

  1. Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966 · 5,250 planned · United States, Argentina, Australia and more
  2. May 29, 2024Phase 1 study in Healthy VolunteerAstraZeneca · NCT06514157 · 14 enrolled · China
  3. Aug 19, 2024Phase 4 study in Respiratory HypersensitivityAstraZeneca · NCT06563102 · 101 enrolled · United States
  4. Sep 6, 2024unither-pharmaceuticals-france's first study: phase 1 study in HealthyNew to unither-pharmaceuticals-franceunither-pharmaceuticals-france · NCT06595121 · 24 enrolled · Turkey
  5. Sep 11, 2024Phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252 · 308 enrolled · United States, Spain
  6. Nov 20, 2024Phase 4 study in Glomerulonephritis, IGACalliditas Therapeutics AB · NCT06712407 · 60 enrolled · United States, Puerto Rico
  7. Mar 29, 2025Lunan Pharmaceutical Group's first study: no phase study in Bioequivalence Study in Healthy SubjectsNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06924190 · 32 enrolled · China
  8. Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950 · 56 planned · Germany, United Kingdom
  9. Feb 20, 2026Phase 1 study in AsthmaAstraZeneca · NCT07433569 · 16 enrolled · United States
  10. Aug 24, 2026Chenpon Pharmaceutical's first study: phase 3 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07790159 · 338 enrolled · China
  11. Aug 31, 2026Phase 2 study in AsthmaChenpon Pharmaceutical · NCT07807007 · 150 enrolled · China
  12. Aug 31, 2026Phase 1 study in AsthmaChenpon Pharmaceutical · NCT07804303 · 30 enrolled · China
  13. Oct 13, 2026triastek-lnc's first study: phase 1 study in Glomerulonephritis, IGANew to triastek-lnctriastek-lnc · NCT07897240 · 18 planned · China
  14. Nov 3, 2026Phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07925216 · 18 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07897240
  2. Dec 2026Primary completion: phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252
  3. Dec 2026Primary completion: phase 4 study in Colitis, UlcerativeBausch Health Companies · NCT04314375
  4. Jan 2027Primary completion: phase 1 study in Glomerulonephritis, IGAtriastek-lnc · NCT07925216

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07925216Glomerulonephritis, IGA · China1Active, not recruitingtriastek-lncJan 202718
NCT07897240Glomerulonephritis, IGA · China1Not yet recruitingtriastek-lncDec 202618
NCT07807007Asthma · China2CompletedChenpon PharmaceuticalAug 3, 2026150
NCT07804303Asthma · China1CompletedChenpon PharmaceuticalJan 22, 202430
NCT07790159Asthma · China3CompletedChenpon PharmaceuticalSep 27, 2024338
NCT07433569Asthma · United States1CompletedAstraZenecaJun 26, 202616
NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom4RecruitingAstraZenecaMay 31, 202756
NCT06924190Bioequivalence Study in Healthy Subjects · China–CompletedLunan Pharmaceutical GroupJan 20, 202532
NCT06712407Glomerulonephritis, IGA · United States, Puerto Rico4Active, not recruitingCalliditas Therapeutics ABMar 202760
NCT06596252Eosinophilic Esophagitis · United States, Spain3Active, not recruitingDr. Falk PharmaDec 2026308
NCT06595121Healthy · Turkey1Completedunither-pharmaceuticals-franceSep 16, 202424
NCT06563102Respiratory Hypersensitivity · United States4CompletedAstraZenecaFeb 24, 2026101
NCT06514157Healthy Volunteer · China1CompletedAstraZenecaSep 9, 202414
NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 3, 20275,250
NCT06268301Healthy Volunteers · United States1CompletedTakedaFeb 17, 202320
NCT06245551Asthma, Exercise-Induced · Russia3CompletedAstraZenecaJun 29, 202464
NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedAstraZenecaJan 22, 2026171
NCT05970263Pulmonary Disease, Chronic Obstructive4WithdrawnAstraZenecaDec 31, 20250
NCT05755906Asthma · United States, Canada, Czechia and more3CompletedAstraZenecaNov 19, 2024374
NCT05519514Healthy Subjects · India1CompletedAbbottAug 8, 202156
NCT05429775Healthy Volunteers · United Kingdom1CompletedNovartisJan 29, 201912
NCT05322707Asthma · United States3Completedcipla-ltdAug 15, 20231,485
NCT05202262Asthma · United States, Canada, Germany and more3CompletedAstraZenecaFeb 26, 2025645
NCT05214599Eosinophilic Esophagitis2Withdrawnbazell-pharma-agNov 20240
NCT05148312Pharmacokinetics · Bulgaria1Completedaquilon-pharmaceuticals-s-aDec 24, 202129
NCT04933383Asthma · Belgium2Completedaquilon-pharmaceuticals-s-aDec 31, 202223
NCT04854538Healthy · Egypt1CompletedGenuine Research Center, EgyptOct 1, 202030
NCT04609904Asthma · United States, Brazil, China and more3CompletedAstraZenecaMar 20, 20252,187
NCT04609878Asthma · United States, Argentina, Belgium and more3CompletedAstraZenecaMar 21, 20252,274
NCT04541043Glomerulonephritis, IGA · United States, Argentina, Australia and more3CompletedCalliditas Therapeutics ABFeb 26, 2024119
NCT04494321Asthma · Taiwan1CompletedIntech BiopharmNov 17, 201799
NCT04314375Colitis, Ulcerative · United States4RecruitingBausch Health CompaniesDec 202670
NCT04234464Asthma, Exercise-Induced · United States3Completedbond-avillion-2-development-lpAug 28, 202060
NCT04132570Rhinitis · China4CompletedJohnson & JohnsonJan 22, 2020206
NCT04080713Healthy · India1CompletedFerring PharmaceuticalsSep 25, 201924
NCT04032834Asthma · United States1Completedvectura-limitedMay 22, 201734
NCT03769090Asthma · United States, Argentina, Canada and more3Completedbond-avillion-2-development-lpAug 19, 20213,132
NCT03755557Rhinitis, Allergic · Austria3Completedmarinomed-biotech-agApr 5, 201982
NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands3CompletedAstraZenecaNov 11, 201923
NCT03643965Glomerulonephritis, IGA · United States, Argentina, Australia and more3CompletedCalliditas Therapeutics ABJul 10, 2023365
NCT03412682Colitis, Ulcerative · Japan3CompletedFerring PharmaceuticalsMay 11, 2020274
NCT03421730Respiratory Sounds · United States1Completedvectura-limitedMar 21, 201817
NCT03245840Eosinophilic Esophagitis · United States3TerminatedTakedaApr 26, 2022133
NCT03015259Asthma · United States3Completedkindeva-drug-deliveryFeb 8, 20181,762
NCT02972866Rhinitis, Allergic, Perennial · Brazil3WithdrawnEurofarma LaboratoriosNov 20190
NCT02853578Asthma · Brazil3SuspendedAche Laboratorios FarmaceuticosOct 202080
NCT02850484Asthma1CompletedIntech BiopharmMay 201699
NCT02800824Healthy1CompletedPadagisJun 2016
NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedAstraZenecaDec 1, 20172,389
NCT02736409Eosinophilic Esophagitis · United States3CompletedTakedaNov 12, 2019219
NCT03262012Pulmonary Disease, Chronic Obstructive · Japan3CompletedAstraZenecaJun 15, 2018416
NCT03073057Asthma · Finland1CompletedOrion Corporation, Orion PharmaMar 201620
NCT02631941Asthma · United Kingdom1CompletedZambon SpAJul 201691
NCT02605837Eosinophilic Esophagitis · United States3CompletedTakedaJan 24, 2019318
NCT02550418Colitis, Ulcerative · Germany2CompletedDr. Falk PharmaMar 201760
NCT02536508Pulmonary Disease, Chronic Obstructive · United States3CompletedAstraZenecaSep 12, 2017627
NCT02533505Pulmonary Disease, Chronic Obstructive · United States4CompletedAstraZenecaAug 12, 201651
NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedAstraZenecaJan 5, 20181,902
NCT02493335Eosinophilic Esophagitis · Germany3CompletedDr. Falk PharmaNov 28, 2018204
NCT02495168Asthma · United States3CompletedTeva Pharmaceutical IndustriesMay 31, 20181,714

How it is read

Names in the registry

  • “Budesonide”, 45 entries
  • “budesonide”, 18 entries
  • “budesonide/formoterol”, 10 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries
  • “BFF MDI 320/9.6 μg”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.